Active Ingredient History
Ursodoxicoltaurine is the international nonproprietary name (INN) for the pharmaceutical form of tauroursodeoxycholic acid (TUDCA). It is also known as taurursodiol. Tauroursodeoxycholic acid is a naturally occurring hydrophilic bile acid which is the taurine conjugated form of ursodeoxycholic acid (UDCA). Humans have only trace amounts of tauroursodeoxycholic acid but bears have large amounts of tauroursodeoxycholic acid and ursodeoxycholic acid in their bile. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Amyotrophic Lateral Sclerosis (approved 2022)
Cholestasis (approved 1983)
Liver Cirrhosis, Biliary (approved 1989)
Acute-On-Chronic Liver Failure (Phase 4)
Adenomatous Polyposis Coli (Phase 2/Phase 3)
Adolescent (Phase 2)
Aged (Phase 1)
Alzheimer Disease (Phase 2)
Amyloidosis (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 3)
Anemia, Hemolytic (Phase 4)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 1)
Autoimmune Diseases (Phase 4)
Barrett Esophagus (Phase 2)
Bile Duct Diseases (Phase 2)
Biliary Tract (Phase 1/Phase 2)
Biliary Tract Diseases (Phase 2)
Cardiomyopathies (Phase 2)
Chemical and Drug Induced Liver Injury (Phase 4)
Child Nutrition Disorders (Phase 2/Phase 3)
Cholangitis (Phase 2)
Cholangitis, Sclerosing (Phase 3)
Cholecystitis, Acute (Phase 3)
Cholecystolithiasis (Phase 4)
Cholelithiasis (Phase 4)
Cholestasis (Phase 2/Phase 3)
Cholestasis, Intrahepatic (Phase 3)
Colitis, Ulcerative (Phase 2/Phase 3)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 3)
Cystic Fibrosis (Phase 2)
Diabetes, Gestational (Phase 4)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetes Mellitus, Type 1 (Phase 1/Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Diarrhea (Phase 4)
Digestive System Diseases (Phase 2)
Duodenal Neoplasms (Phase 2/Phase 3)
Dyspepsia (Phase 4)
Esophageal Neoplasms (Phase 2)
Fatigue (Phase 4)
Fibrosis (Phase 1/Phase 2)
Gallstones (Phase 4)
Gastrointestinal Diseases (Phase 2)
General Surgery (Phase 1)
Glucose Intolerance (Phase 1)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Hepatitis (Phase 4)
Hepatitis, Autoimmune (Phase 4)
Hepatitis B (Phase 2)
Hepatitis C, Chronic (Phase 3)
Hepatitis D (Phase 2)
Huntington Disease (Phase 1)
Hypertension (Phase 1/Phase 2)
Hypertension, Portal (Phase 2)
Inflammation (Phase 2)
Intestinal Polyps (Phase 2/Phase 3)
Jaundice, Obstructive (Phase 2)
Kidney Failure, Chronic (Phase 4)
Liver Cirrhosis (Phase 1/Phase 2)
Liver Cirrhosis, Biliary (Phase 4)
Liver Diseases (Phase 3)
Multiple Sclerosis (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 2)
Neurodegenerative Diseases (Phase 3)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obesity, Morbid (Phase 4)
Overweight (Phase 1)
Pancreatitis (Phase 3)
Parkinson Disease (Phase 3)
Polycystic Kidney, Autosomal Dominant (Phase 2)
Pouchitis (Phase 2/Phase 3)
Pregnancy (Phase 3)
Pregnancy Complications (Phase 3)
Presbyopia (Phase 2)
Radiation Oncology (Phase 2)
Retinal Diseases (Phase 1)
Sepsis (Phase 2/Phase 3)
Short Bowel Syndrome (Phase 4)
Supranuclear Palsy, Progressive (Phase 3)
Thoracic Surgery (Phase 4)
Transaminases (Phase 2)
Wolfram Syndrome (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue